Revance Therapeutics, Inc.
Revance Therapeutics, Inc., a leading biotechnology company headquartered in the United States, focuses on innovative aesthetic and therapeutic solutions. Founded in 2011, Revance has made significant strides in the industry, particularly with its proprietary DaxibotulinumtoxinA injection, which offers a unique, long-lasting alternative to traditional neuromodulators. With a strong presence in the aesthetic and therapeutic sectors, Revance is committed to advancing patient care through its cutting-edge products. The company has achieved notable milestones, including successful clinical trials and regulatory approvals, positioning itself as a key player in the competitive landscape of biotechnology. Revance's dedication to innovation and quality sets it apart, making it a trusted name in the field.
DitchCarbon Score
How does Revance Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Revance Therapeutics, Inc.'s score of 18 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Revance Therapeutics, Inc.'s reported carbon emissions
Revance Therapeutics, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for the most recent year, nor specific reduction targets or initiatives outlined in their climate commitments. Without concrete emissions figures or defined reduction strategies, it is challenging to assess their environmental impact or commitment to sustainability. In the context of the biopharmaceutical industry, companies are increasingly focusing on reducing their carbon footprints and setting ambitious climate goals. While Revance may not have disclosed specific data or targets, the industry trend suggests a growing emphasis on sustainability and climate responsibility. As such, stakeholders may look forward to future disclosures that could highlight Revance's efforts in addressing climate change and reducing carbon emissions.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Revance Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
